



→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 32

Complete If Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D
Attorney Docket Number	15270J-004747US

### U.S. PATENT DOCUMENTS

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DK	578	6,875,434	04-05-2005	Schenk	
	577	6,866,849	03-15-2005	Schenk	
	575	6,866,850	03-15-2005	Schenk	
	583	2004/0265919 A1	12-30-2004	Vanderstichle et al.	
	581	2004/0247612 A1	12-09-2004	Wang	
	582	2004/0241164 A1	12-02-2004	Bales et al.	
	576	6,818,218	11-16-2004	Schenk	
	563	6,787,637	09-07-2004	Schenk et al.	
	572	6,761,888	07-13-2004	Schenk	
	562	6,750,324	06-15-2004	Schenk et al.	
	573	6,743,427	06-01-2004	Schenk	
	442	6,713,450 B2	03-30-2004	Frangione et al.	
	444	2004/0043418 A1	03-04-2004	Holtzman et al.	
	415	2003/0166558 A1	09-04-2003	Frangione et al.	
	431	2003/0165496 A1	09-04-2003	Basi et al.	
	432	6,562,341 B2	05-13-2003	Prusiner et al.	
	370	2003/0068325 A1	04-10-2003	Wang	
	440	2003/0068316 A1	04-10-2003	Klein et al.	
	378	2002/0197258 A1	12-26-2002	Ghanbari et al.	
	366	2002/0187157 A1	12-12-2002	Jensen et al.	
	377	2002/0168377 A1	11-14-2002	Schaetzl	
	340	2002/0162129 A1	10-31-2002	Lannfelt	
	395	2002/0160394 A1	10-31-2002	Wu	
	326	2002/0136718 A1	09-26-2002	Raso	
	379	2002/0132268 A1	09-19-2002	Chang et al.	
	365	2002/0133001 A1	09-19-2002	Geftter et al.	
	325	2002/0102261 A1	08-01-2002	Raso	
	362	2002/0094335 A1	07-18-2002	Chalifour et al.	
	306	6,417,178 B1	07-09-2002	Klunk et al.	
	376	2002/0086847 A1	07-04-2002	Chain	
	345	2002/0077288 A1	06-20-2002	Frangione	
	405	6,399,314 B1	06-04-2002	Krishnamurthy	

Examiner Signature

Date Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60554673

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 32

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D
Attorney Docket Number	15270J-004747US

DK	453	2002/0058267 A1	05-16-2002	Ozenberger et al.
	342	2002/0009445 A1	01-24-2002	Du et al.
	511	6,331,440	12-18-2001	Nordstedt, et al.
	416	6,303,567 B1	10-16-2001	Findels et al.
	267	6,294,171 B2	09-25-2001	McMichael
	381	2001/0021769 A1	09-13-2001	Prusiner
	401	6,284,533 B1	09-04-2001	Thomas
	234	6,284,221 B1	09-04-2001	Schenk, et al.
	300	2001/0018053 A1	08-30-2001	McMichael
	516	6,261,569	07-17-2001	Comis et al.
	230	6,262,335 B1	07-17-2001	Hsiao et al.
	452	6,218,506 B1	04-17-2001	Krafft et al.
	196	6,150,091	11-21-2000	Pandolfo et al.
	231	6,114,133	09-05-2000	Seubert et al.
	1	6,057,367	05-02-2000	Stamler et al.
	510	6,022,859	02-08-2000	Klessling, et al.
	221	5,989,566	11-23-1999	Cobb et al.
	417	5,985,242	11-16-1999	Findels et al.
	2	5,958,883	09-28-1999	Snow
	3	5,955,317	09-21-1999	Suzuki et al.
	4	5,955,079	09-21-1999	Mond et al.
	346	5,935,927	08-10-1999	Vitek et al.
	512	5,891,991	04-06-1999	Wasco et al.
	5	5,877,399	03-02-1999	Hsiao et al.
	6	5,869,093	02-09-1999	Weiner et al.
	7	5,869,054	02-09-1999	Weiner et al.
	445	5,854,215	12-29-1998	Findels et al.
	8	5,854,204	12-29-1998	Findels et al.
	9	5,851,996	12-22-1998	Kline
	10	5,849,298	12-15-1998	Weiner et al.
	382	5,846,533	12-08-1998	Prusiner
	321	5,837,672	11-17-1998	Schenk et al.
	11	5,837,473	11-17-1998	Maggio et al.
	353	5,824,322	10-20-1998	Balasubramanian
	446	5,817,626	10-06-1998	Findels et al.

Examiner  
SignatureDate  
Considered

1/16/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60554673

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D
Attorney Docket Number	15270J-004747US

JK	12	5,786,180	07-28-1998	Konig et al.
	207	5,780,587	07-14-1998	Potter
	357	5,776,468 B1	07-07-1998	Hauser et al.
	451	5,766,846	06-16-1998	Schlossmacher et al.
	13	5,753,624	05-19-1998	McMichael et al.
	380	5,750,361	05-12-1998	Prusiner et al.
	14	5,750,349	05-12-1998	Suzuki et al.
	197	5,744,368	04-28-1998	Goldgaber et al.
	211	5,736,142	04-07-1998	Sette et al.
	15	5,733,547	03-31-1998	Weiner et al.
	373	5,721,130	02-24-1998	Seubert et al.
	16	5,688,651	11-18-1997	Solomon
	17	5,679,348	10-21-1997	Nesburn et al.
	515	5,652,334	07-29-1997	Roberts
	18	5,645,820	07-08-1997	Hafler et al.
	19	5,641,474	06-24-1997	Hafler et al.
	20	5,641,473	06-24-1997	Hafler et al.
	356	5,622,701	04-22-1997	Berg
	21	5,612,486	03-18-1997	McConlogue et al.
	22	5,605,811	02-25-1997	Seubert et al.
	320	5,593,846	01-14-1997	Schenk et al.
	584	5,589,154	12-31-1996	Anderson
	23	5,585,100	12-17-1996	Mond et al.
	358	5,583,112 B2	12-10-1996	Kensil et al.
	574	5,576,184	11-19-1996	Better et al.
	24	5,571,500	11-05-1996	Hafler et al.
	25	5,571,499	11-05-1996	Hafler et al.
	513	5,514,548	05-07-1996	Krebbet et al.
	514	5,470,951	11-28-1995	Roberts
	403	5,464,823	11-07-1995	Lehrer et al.
	175	5,441,870	08-15-1995	Seubert, et al.
	26	5,434,170	07-18-1995	Andrusis, Jr.
	27	5,387,742	02-07-1995	Cordell
	543	5,278,049	01-11-1994	Baker et al.
	181	5,270,165	12-14-1993	Van Nostrand et al.

Examiner Signature

*Janice E. Keltin*

Date Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

60554673

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D
Attorney Docket Number	15270J-004747US

✓	284	5,231,170	07-27-1993	Averback
	28	5,231,000	07-27-1993	Majocha et al.
	29	5,220,013	06-15-1993	Ponte et al.
	30	5,208,036	05-04-1993	Eppstein et al.
	31	5,192,753	03-09-1993	McGeer et al.
	32	5,187,153	02-16-1993	Cordell et al.
	548	5,096,706	03-17-1992	Flint
	33	5,057,540	10-15-1991	Kensil et al.
	198	5,004,697	04-20-1991	Pardridge
	570	4,912,206	03-27-1990	Goldgaber et al.
✓	402	4,713,368	12-15-1987	Stevens
	34	4,666,829	05-19-1987	Glenner et al.

**U.S. PATENT APPLICATIONS**

Examiner	Cite No. <sup>1</sup>	Document Number	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
✓ DK	296	60/254,465	12-08-2000	Holtzman et al.	
DK	297	60/254,498	12-08-2000	Holtzman et al.	
DK	305	09/724,842	11-28-2000	Chalifour et al.	
✓	299	60/186,295	03-01-2000	Rasmussen et al.	
	295	60/184,601	02-24-2000	Holtzman et al.	
	282	60/169,687	12-08-1999	Chain	
✓	242	60/168,594	11-29-1999	Chalifour et al.	
DK	283	09/441,140	11-16-1999	Solomon et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>6</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	533	AU	707083		07-01-1999			
	343	EP	1 172 378	A1	01-16-2002			
	48	EP	506 785	B1	03-15-2000			
	43	EP	639 081	B1	11-03-1999			
	46	EP	561 087	B1	08-04-1999			
	35	EP	911 036	A2	04-28-1999			

Examiner Signature

*Janice E. Reiter*

Date Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

60554673

→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 32

*Complete If Known*

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D
Attorney Docket Number	15270J-004747US

✓K	42	EP	652 962	B1	12-16-1998			
1	36	EP	868 918	A2	10-07-1998			
	37	EP	863 211	A1	09-09-1998			
	38	EP	845 270	A1	06-03-1998			
	523	EP	752 886	B1	01-28-1998			
	45	EP	594 607	B1	08-27-1997			
	39	EP	782 859	A1	07-09-1997			
	187	EP	783 104	A1	07-09-1997			
	47	EP	526 511	B1	05-28-1997			
	50	EP	440 619	B1	01-24-1996			
	51	EP	359 783	B1	11-29-1995			
	40	EP	683 234	A1	11-22-1995			
	41	EP	666 080	A1	08-09-1995			
	44	EP	613 007	A2	08-31-1994			
	52	EP	276 723	B1	12-08-1993			Yes
	49	EP	451 700	A1	10-16-1991			
	93	GB	2 335 192	A	09-15-1999			
	92	GB	2 220 211	A	01-04-1990			
	587	JP	7-165799	A	06-27-1995			abst. only
	585	WO	04/080419	A2	09-23-2004			
	579	WO	04/031400	A2	04-15-2004			
	571	WO	04/13172	A2, A3	02-12-2004			
	441	WO	03/104437	A2	12-18-2003			
	586	WO	03/077858	A2, A3	09-25-2003			
	433	WO	03/20212	A2	03-13-2003			
	458	WO	02/60481	A1	08-08-2002			
	457	WO	02/46237	A1	06-13-2002			
	351	WO	02/34878	A2	05-02-2002			
	557	WO	02/88307	A2	11-07-2002			
	556	WO	02/88306	A2	11-07-2002			
	352	WO	02/34777	A1	05-02-2002			
	456	WO	02/21141	A2	03-14-2002			
	341	WO	02/03911	A2	01-17-2002			
	344	WO	01/90182	A2	11-29-2001			
↓	348	WO	01/77167	A2	10-18-2001			

Examiner Signature

Date Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60554673

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D
Attorney Docket Number	15270J-004747US

294	WO	01/62801	A2	08-30-2001			
301	WO	01/62284	A2	08-30-2001			
298	WO	01/42306	A2	06-14-2001			
243	WO	01/39796	A2	06-07-2001			
450	WO	01/18169	A3	03-15-2001			
455	WO	01/10900	A2	02-15-2001			
199	WO	00/77178	A1	12-21-2000			
322	WO	00/72880	A2, A3	12-07-2000			
323	WO	00/72876	A2, A3	12-07-2000			
324	WO	00/72870	A1	12-07-2000			
529	WO	00/68263	A2	11-16-2000			
240	WO	00/43039	A1	07-27-2000			
188	WO	00/43049	A1	07-27-2000			
519	WO	00/26238	A2	05-11-2000			
555	WO	00/23082	A1	04-27-2000			
522	WO	00/20027	A2	04-13-2000			
53	WO	99/60024	A1	11-25-1999			
55	WO	99/58564	A1	11-18-1999			
54	WO	99/60021	A2	11-15-1999			
331	WO	99/06545	A2	11-02-1999			
57	WO	99/27949	A1	06-10-1999			
58	WO	99/27944	A1	06-10-1999			
59	WO	99/27911	A1	06-10-1999			
526	WO	99/06587	A2	02-11-1999			
56	WO	99/06066	A2	02-11-1999			
203	WO	99/00150	A2	01-07-1999			
60	WO	98/44955	A1	10-15-1998			
454	WO	98/33815	A1	08-06-1998			
520	WO	98/22120	A1	05-28-1998			
530	WO	98/08868	A1	03-05-1998			
61	WO	98/07850	A2	02-26-1998			
521	WO	98/05350	A1	02-12-1998			
525	WO	98/02462	A1	01-22-1998			
527	WO	97/32017	A1	09-04-1997			
202	WO	97/21728	A1	06-19-1997			
62	WO	97/17613	A1	05-15-1997			

Examiner Signature



Date Considered

12/16/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60554673

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

7 of 32

*Complete if Known*

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D
Attorney Docket Number	15270J-004747US

✓K	383	WO	97/10505	A1	03-20-1997			
1	528	WO	97/08320	A1	03-06-1997			
	63	WO	96/39176	A1	12-12-1996			
	532	WO	96/37621	A2	11-28-1996			
	208	WO	96/28471	A1	09-19-1996			
	64	WO	96/25435	A1	08-22-1996			
	65	WO	96/18900	A1	06-20-1996			
	66	WO	95/31996	A1	11-30-1995			
	518	WO	95/23166	A1	08-31-1995			
	200	WO	95/12815	A1	05-11-1995			
	67	WO	95/11994	A1	05-04-1995			
	68	WO	95/11311	A1	04-27-1995			
	227	WO	95/11008	A2	04-27-1995			
	531	WO	95/08999	A1	04-06-1995			
	69	WO	95/05853	A1	03-02-1995			
	524	WO	95/05393	A2	02-23-1995			<input type="checkbox"/>
	70	WO	95/04151	A2	02-09-1995			
	201	WO	94/28412	A1	12-08-1994			
	517	WO	94/05311	A1	03-17-1994			
	71	WO	94/03615	A1	02-17-1994			
	72	WO	94/01772	A1	01-20-1994			
	73	WO	93/21950	A1	11-11-1993			
	74	WO	93/16724	A1	09-02-1993			
	75	WO	93/15760	A1	08-19-1993			
	76	WO	93/14200	A1	07-22-1993			
	205	WO	93/04194	A1	03-04-1993			
	77	WO	93/02189	A1	02-04-1993			
	78	WO	92/13069	A1	08-06-1992			
	79	WO	92/06708	A1	04-30-1992			
	80	WO	92/06187	A1	04-16-1992			
	81	WO	91/19810	A1	12-26-1991			
	82	WO	91/16819	A1	11-14-1991			
	83	WO	91/12816	A1	09-05-1991			
	84	WO	91/08760	A1	06-27-1991			
↓	85	WO	90/12871	A1	11-01-1990			
	86	WO	90/12870	A1	11-01-1990			

Examiner Signature

Date Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60554673

→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 32

## Complete If Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D
Attorney Docket Number	15270J-004747US

DK	89	WO	89/06689	A1	07-27-1989			
	88	WO	89/06242	A1	07-13-1989			
	90	WO	89/03687	A1	05-05-1989			
	87	WO	89/01343	A1	02-23-1989			
↓	91	WO	88/10120	A1	12-29-1988			

Examiner Signature

Date Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60554673

AUG 04 2005

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 32

**Complete if Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.
Attorney Docket Number	15270J-004747US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DK	391	AGUZZI et al., "Prion research: the next frontiers," <u>Nature</u> , 389:795-798 (1997).
✓	372	AKIYAMA et al., "Occurrence of the Diffuse Amyloid $\beta$ -Protein (A $\beta$ ) Deposits With Numerous A $\beta$ -Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease," <u>Glia</u> , 25:324-331 (1999).
	393	AKIYAMA et al., "Inflammation and Alzheimer's disease," <u>Neurobiology of Aging</u> , 21:383-421 (2000).
	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?", <u>Neurology</u> , 45:1441-1445 (1995).
	448	ANDREW et al., <u>Current Protocols in Immunology</u> , 2.7.1-2.9.8, John Wiley & Sons, Inc. (1997).
	484	ARENDASH et al., "Behavioral assessment of Alzheimer's transgenic mice following long-term A $\beta$ vaccination: Task specificity and correlations between A $\beta$ deposition and spatial memory," <u>DNA and Cell Biology</u> , 20(11):737-744 (2001).
	95	Associated Press, "Immune cells may promote Alzheimer's, a study finds," <u>The Boston Globe</u> (4/13/95). <input type="checkbox"/>
	485	BACSKAI et al., "Imaging of amyloid- $\beta$ deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy," <u>Nature Medicine</u> , 7(3):369-372 (2001).
	504	BALBACH et al., "Amyloid fibril formation by A $\beta$ <sub>15-22</sub> , a seven-residue fragment of the Alzheimer's $\beta$ -amyloid peptide, and structural characterization by solid state NMR," <u>Biochemistry</u> , 39:13748-13759 (2000).
	176	BARD et al., "Peripherally administered antibodies against amyloid $\beta$ -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <u>Nature Medicine</u> , 6(8):916-919 (2000). <input type="checkbox"/>
	550	BARD et al., "Epitope and isotype specificities of antibodies to $\beta$ -amyloid peptide for protection against Alzheimer's disease-like neuropathology," <u>PNAS</u> , 100(4):2023-2028 (2003).
	228	BARROW et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra," <u>J. Mol. Biol.</u> , 225(4):1075-1093 (1992).
✓	96	BAUER et al., "Interleukin-6 and $\alpha$ -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Letters</u> , 285(1):111-114 (1991). <input type="checkbox"/>

Examiner Signature

Date Considered

1/6/06

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60554673

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


Sheet 10 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.
Attorney Docket Number	15270J-004747US

JK	239	BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET.	
1	561	BELLOTTI et al., "Application of Monoclonal Anti-idiotypes in the Study of AL Amyloidosis: Therapeutic Implications," <i>Renal Failure</i> , 15(3):365-371 (1993).	
	404	BENJAMINI et al., from <i>IMMUNOLOGY A Short Course</i> , Second Edition, Chapter 4, Antibody Structure, pages 49-65, 1991, published by Wiley-Liss, Inc., New York, New York.	
	558	BENJAMINI et al., from <i>IMMUNOLOGY A Short Course</i> , Second Edition, pages 136-138, 143, 73-74, 372-373, and 400-401, 1991, published by Wiley-Liss, Inc., New York, New York.	
	540	BENKIRANE, et al, "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," <i>J. Biol. Chem.</i> , 268(23):26279-26285 (1993).	
	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <i>Eur. J. Immunol.</i> , 29:345-354 (1999).	
	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <i>Soc. for Neuroscience Abstracts</i> , 18:764 (1992).	
	97	BLASS, "Immunologic Treatment of Alzheimer's Disease," <i>New England J. Medicine</i> , 341(22):1694 (1999).	<input type="checkbox"/>
	98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <i>Biochem. Biophys. Res. Comm.</i> , 171(2):890-897 (1990).	<input type="checkbox"/>
	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <i>Neuron</i> , 19:939-945 (1997).	<input type="checkbox"/>
	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <i>Cur. Opin. Genetic Develop.</i> , 3:102-109 (1993).	<input type="checkbox"/>
	419	BORK et al., "Go hunting in sequence databases but watch out for the traps," <i>Trends in Genetics</i> , 12(10):425-427 (1996).	
	418	BORK, P., "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <i>Genome Research</i> , 10:398-400 (2000).	
	420	BRENNER, S. E., "Errors in genome annotation," <i>Trends in Genetics</i> , 15(4):132-133 (1999).	
V	101	BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717 : Val>Ile) in 85 cases of early onset Alzheimer's disease," <i>J. Neurology, Neurosurg. Psychiatry</i> , 56:112-115 (1993).	<input type="checkbox"/>

Examiner Signature



Date Considered

1/6/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60554673

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 32

**Complete if Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.
Attorney Docket Number	15270J-004747US

<b>DK</b>	461	BURDICK et al., "Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide antigens," <u>J. Biol. Chem.</u> , 267:546-555 (1992).	
	327	CAMERON, "Recent Advances in Transgenic Technology," <u>Molecular Biotechnology</u> , 7:253-265 (1997).	
	285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <u>Clin. Neuropharmac.</u> , 15:414A-414B (1992).	
	421	CASTILLO et al., "Amylin / Islet Amyloid Polypeptide: Biochemistry, Physiology, Patho-Physiology," <u>Diabète &amp; Métabolisme (Paris)</u> , 21:3-25 (1995).	
	224	Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at: <a href="http://www.fda.gov/cber/vaccine/thimerosal.htm">http://www.fda.gov/cber/vaccine/thimerosal.htm</a> , last updated May 16, 2002.	
	102	CHAO et al., "Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury," <u>Soc. Neurosci. Abstracts</u> , 19:513-7 (1993). <input style="width: 20px; height: 20px; vertical-align: middle;" type="checkbox"/>	
	266	CHAPMAN, "Model behavior," <u>Nature</u> , 408:915-916 (2000).	
	349	CHECK, "Battle of the Mind," <u>Nature</u> , 422:370-372 (2003).	
	222	Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.)	
	332	CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice," <u>Progress in Brain Research</u> , 117:327-337 (1998).	
	307	CHEN et al., "A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease," <u>Nature</u> , 408(6815):975-979 (2000).	
	213	CHEN et al., "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <u>Neuroscience Letters</u> , 125:223-226 (1991).	
	542	CHISHTI et al., "Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695," <u>J. Biol. Chem.</u> , 276(24):21562-70 (2001).	
	566	CHOTHIA et al., "Domain Association in Immunoglobulin Molecules," <u>J. Mol. Biol.</u> , 186:651-663 (1985).	
✓	302	CHUNG et al., "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β-Peptide by Microglial Cells," <u>J. Biol. Chem.</u> , 274(45):32301-32308 (1999).	

Examiner Signature



Date Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60554673

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.
Attorney Docket Number	15270J-004747US

	<b>509</b> CIRRITO et al., "Amyloid $\beta$ and Alzheimer disease therapeutics: the devil may be in the details," <u>J. Clin. Invest.</u> , 112:321-323 (2000).	
	<b>462</b> CO et al., "Chimeric and humanized antibodies with specificity for the CD33 antigen," <u>J. Immunol.</u> , 148:1149-1154 (1992).	
	<b>291</b> COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," <u>Pharm. Res.</u> , 17:266-274 (2000).	
	<b>333</b> CONWAY et al., "Acceleration of oligomerization, not fibrillation, is a shared property of both $\alpha$ -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <u>PNAS</u> , 97(2):571-576 (2000).	
	<b>286</b> CORDELL, B., " $\beta$ -Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>Ann. Rev. Pharmacol. Toxicol.</u> , 34:69-89 (1994).	
	<b>287</b> COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand. J. Immunol.</u> , 38:177-182 (1993).	
	<b>541</b> CRIBBS et al., "All-D-Erantiomers of Beta-Amyloid Exhibit Similar Biological Properties to All-L-Beta-Amyloids," <u>J. Biol. Chem.</u> , 272:7431-7436 (1997).	
	<b>293</b> DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," <u>Life Sci.</u> , 63:2121-2131 (1998).	
	<b>412</b> DAS et al., "Amyloid- $\beta$ Immunization Effectively Reduces Amyloid Deposition in FcRy Knock-Out-Mice," <u>J. Neuroscience</u> , 23(24):8532-8538 (2003).	
	<b>469</b> DEMATTOS et al., "Peripheral anti- $A\beta$ antibody alters CNS and plasma clearance and decreases $A\beta$ burden in a mouse model of Alzheimer's disease," <u>PNAS</u> , 98(15):8850-8855 (2001).	
	<b>214</b> DEMATTOS et al., "Peripheral Anti $A\beta$ Antibody Alters CNS And Plasma $A\beta$ Clearance and Decreases Brain $A\beta$ Burden in a Mouse Model of Alzheimer's Disease," <u>PNAS early edition</u> , 10.1073/pnas.151261398 (2001).	
	<b>493</b> DEMATTOS et al., "Plaque-associated disruption of CSF and plasma amyloid- $\beta$ ( $A\beta$ ) equilibrium in a mouse model of Alzheimer's disease," <u>J. Neurochem.</u> , 81:229-236 (2002).	
	<b>220</b> Dialog/Derwent, Abstract of WPI Acc No: 1997-054436/199706: Stable vaccine compsns. - comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water, Derwent File 351: Derwent WPI database. (Publication date unknown.)	
	<b>486</b> DICKEY et al., "Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated $\beta$ -amyloid 1-42 peptide," <u>DNA and Cell Biology</u> , 20(11):723-729 (2001).	

Examiner Signature



Date Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60554673

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 32

**Complete if Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.
Attorney Docket Number	15270J-004747US

<i>JK</i>	436	DICKSON et al., "Neuroimmunology of Alzheimer's disease: a conference report," <u>Neurobiology of Aging</u> , 13(6):793-798 (1992), abstract only
	390	DIOMEDE et al., "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes," <u>Biochem. J.</u> , 320:563-570 (1996).
	363	DODART, "Immunotherapy for Alzheimer's disease: will vaccination work?," <u>Trends in Molecular Medicine</u> , 9(3):85-87 (2003).
	422	DOERKS et al., "Protein annotation: detective work for function prediction," <u>Trends in Genetics</u> , 14(6):248-250 (1998).
	318	DU et al., "Reduced levels of amyloid beta-peptide antibody in Alzheimer disease," <u>Neurology</u> , 57(5):801-5 (2001).
	103	DUFF et al., "Mouse model made," <u>Nature</u> , 373:476-477 (1995).
	288	DUMERY et al., " $\beta$ -Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," <u>Pathol. Biol.</u> , 49:72-85 (2001).
	407	ECK et al., <u>Goodman and Gilman's The pharmacological basis of therapeutics</u> , Chapter 5, pages 77-101 (1996).
	475	EL-AGNAF et al., "The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide," <u>Eur. J. Biochem.</u> , 256(3):560-569 (1998).
	225	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release (1/18/2002).
	226	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002).
	104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983).
	289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?", <u>Trends in Pharm. Sci.</u> , 22:2-3 (2001).
	501	ESLER et al., "Point substitution in the central hydrophobic cluster of a human $\beta$ -amyloid congener disrupts peptide folding and abolishes plaque competence," <u>Biochemistry</u> , 35:13914-13921 (1996).
<i>✓</i>	105	FELSENSTEIN et al., "Processing of the $\beta$ -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 152:185-189 (1993).

Examiner Signature

*Jamie E. Roth*

Date Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60554673

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 14 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.
Attorney Docket Number	15270J-004747US

	<b>328</b> <b>FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing;" <i>Alzheimer's and Parkinson's Diseases</i>, Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995).</b>	
	<b>106</b> <b>FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <i>Neurobiology of Aging</i>, 17(5):809-815 (1996).</b>	
	<b>539</b> <b>FINDEIS et al., "Modified peptide inhibitors of amyloid B-peptide polymerization," <i>Biochemistry</i>, 38:6791-6800 (1999).</b>	
	<b>107</b> <b>FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <i>PNAS</i>, 88:1779-1782 (1991).</b>	
	<b>108</b> <b>FLANDERS et al., "Altered expression of transforming growth factor-<math>\beta</math> in Alzheimer's disease," <i>Neurology</i>, 45:1561-1569 (1995).</b>	
	<b>464</b> <b>FLOOD et al., "An amyloid <math>\beta</math>-Protein fragment, A <math>\beta</math> [12-28], equipotently impairs post-training memory processing when injected into different limbic system structures," <i>Brain Res.</i> 663(2):271-276 (1994).</b>	
	<b>538</b> <b>FLOOD, et al., "Topography of a binding site for small amnestic peptides deduced from structure-activity studies: Relation to amnestic effect of amyloid B protein," <i>PNAS</i>, 91:380-384 (1994).</b>	
	<b>423</b> <b>FONSECA et al., "The Presence of Isoaspartic Acid in <math>\beta</math>-Amyloid Plaques Indicates Plaque Age," <i>Experimental Neurology</i>, 157(2):277-288 (1999).</b>	
	<b>386</b> <b>FRAUTSCHY et al., "Effects of injected Alzheimer <math>\beta</math>-amyloid cores in rat brain," <i>PNAS</i>, 88:8362-8366 (1991).</b>	
	<b>565</b> <b>FRAZER et al., "Immunoglobulins: Structure and Function," chapter 3, pages 37-74 from <i>Fundamental Immunology, fourth edition</i>, W.E. Paul, eds., Lippincott-Raven publishers, Philadelphia (1999).</b>	
	<b>246</b> <b>FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <i>Vaccine</i>, 19:2615-2619 (2001).</b>	
	<b>245</b> <b>FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of <math>\beta</math>-amyloid peptide is essential for modulation of fibrillar aggregation," <i>J. of Neuroimmunology</i>, 95:136-142 (1999).</b>	
	<b>247</b> <b>FRENKEL et al., "Immunization against Alzheimer's <math>\beta</math>-amyloid plaques via EFRH phage administration," <i>PNAS</i>, 97:11455-11459 (2000).</b>	
	<b>248</b> <b>FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's <math>\beta</math>-amyloid peptide represents the epitope of its anti-aggregating antibodies," <i>J. of Neuroimmunology</i>, 88:85-90 (1998).</b>	

Examiner Signature		Date Considered	1/6/06
--------------------	---	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60554673

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
				Application Number	10/828,548
				Filing Date	April 19, 2004
				First Named Inventor	Schenk
				Art Unit	1649
				Examiner Name	Lyles, Johnalyn D.
Sheet	15	of	32	Attorney Docket Number	15270J-004747US

DK	244	FRENKEL, et al., "Modulation of Alzheimer's $\beta$ -amyloid neurotoxicity by site-directed single chain antibody," <i>J. of Neurolimmunology</i> , 106:23-31 (2000).	
	210	FRIEDLAND et al., "Development of an anti- $A\beta$ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <i>Mol. Neurology</i> , 9:107-113 (1994).	
	249	FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in <i>Cerebrovascular Pathology in Alzheimer's Disease</i> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).	
	364	FURLAN et al., "Vaccination with amyloid- $\beta$ peptide induces autoimmune encephalomyelitis in C57/BL6 mice," <i>Brain</i> , 126:285-291 (2003).	
	109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F $\beta$ -amyloid precursor protein," <i>Nature</i> , 373(6514):523-527 (1995).	
	215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with $A\beta_42$ ," <i>Annals of the New York Academy of Science</i> , 920:274-284 (2000).	
	110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <i>TIPS</i> , 13:108-113 (1992).	
	251	GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <i>Biochem. Biophys. Res. Comm.</i> , 173:1292-1298 (1990).	
	111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <i>J. Exp. Med.</i> , 177:1181-1186 (1993).	
	252	GEDDES, "N-terminus truncated $\beta$ -amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," <i>Neurobiology of Aging</i> , 20:75-79 (1999).	
	463	GHISO et al., "Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease," <i>Biochem. J.</i> , 282 (Pt 2):517-522 (1992).	
	470	GIULIAN et al., "Specific domains of $\beta$ -amyloid from Alzheimer plaque elicit neuron killing in human microglia," <i>J. Neurosci.</i> , 16 (19):6021-6037 (1996).	
	253	GIULIAN, et al., "The HHQK Domain of $\beta$ -Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <i>J. Biol. Chem.</i> , 273:29719-29726 (1998).	
✓	112	GLENN et al., "Skin immunization made possible by cholera toxin," <i>Nature</i> , 391:851 (1998).	

Examiner Signature		Date Considered	1/6/06
--------------------	---	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60554673

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 16 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.
Attorney Docket Number	15270J-004747US

<i>DK</i>	114	GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <i>Biochem. Biophys. Res. Comm.</i> , 122(3): 1131-1135 (1984).	
	113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <i>Biochem. Biophys. Res. Comm.</i> , 120(3): 885-890 (1994).	
	115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <i>Nature</i> , 349:704-706 (1991).	
	388	GOLDFARB et al., "The Transmissible Spongiform Encephalopathies," <i>Ann. Rev. Med.</i> , 46:57-65 (1995).	
	424	GOLDSBY et al., "Vaccines," Chapter 18 from <i>Immunology, 4th Edition</i> , W.H. Freeman and Company, New York, pages 449-465 (2000).	
	397	GOLDSTEINS et al., "Goldsteins et al., Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants," <i>PNAS</i> , 96:3108-3113 (1999).	
	303	GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," <i>Immunology</i> , 93:149-153 (1998).	
	503	GOREVIC et al., "Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern" <i>Biochem. and Biophys. Res. Commun.</i> , 147(2):854-862 (1987).	
	237	GORTNER, <i>Outlines of Biochemistry</i> , pp. 322-323, John Wiley & Sons, Inc., New York (1949).	
	116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <i>PNAS</i> , 93:427-432 (1996).	
	190	GRAVINA et al., "Amyloid $\beta$ Protein (A $\beta$ ) in Alzheimer's Disease," <i>J. Biol. Chem.</i> , 270(13):7013-7016 (1995).	
	254	GRUBECK-LOEBENSTEIN, et al., "Immunization with $\beta$ -amyloid: could T-cell activation have a harmful effect?", <i>TINS</i> , 23:114 (2000).	
	117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <i>Vaccine</i> , 15(12/13): 1341-1343 (1997).	
	241	HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," <i>Nature</i> , 359(6393):322-325 (1992).	
<i>✓</i>	487	HAASS et al., "Proteofibrils, the unifying toxic molecule of neurodegenerative disorders?," <i>Nature Neuroscience</i> , 4(9):859-860 (2001).	

Examiner Signature

*Yannick E. Kell*

Date Considered

1/6/06

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60554673

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 17 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.

Attorney Docket Number 15270J-004747US

✓	118	HAGA et al., "Synthetic Alzheimer amyloid $\beta$ /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993).
✓	182	HANAN and SOLOMON, "Inhibitory effect of monoclonal antibodies on Alzheimer's $\beta$ -amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996).
✓	119	HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997).
✓	120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," <u>TINS</u> , 20(4): 154-159 (1997).
✓	121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1996).
✓	255	HARIGAYA, et al., "Modified amyloid $\beta$ protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," <u>Biochem. Biophys. Res. Comm.</u> , 211:1015-1022 (1995).
✓	193	HARRINGTON et al., "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of $\beta$ / A4-protein," <u>Biochimica Biophysica Acta</u> , 1158:120-128 (1993).
✓	229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2," <u>Immunology</u> , 78:643-649 (1993).
✓	476	HE et al., "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P- selectin," <u>J. Immunol.</u> , 160:1029-1035 (1998).
✓	177	HELMUTH, "Further Progress on a $\beta$ -Amyloid Vaccine," <u>Science</u> , 289:375 (2000).
✓	559	HERLYN et al., "Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma", <u>Eur. J. Immunol.</u> , 9:657-659 (1979).
✓	473	HILBICH et al., "Aggregation and secondary structure of synthetic amyloid $\beta$ A4 peptides of Alzheimer's disease," <u>J. Mol. Biol.</u> , 218:149-163 (1991).
✓	471	HILBICH et al., "Substitutions of hydrophobic amino acid reduce the amyloidogenicity of Alzheimer's disease $\beta$ A4 peptides" <u>J. Mol. Biol.</u> , 228:460-473 (1992).
✓	236	HILBICH et al., "Human and rodent sequence analogs of Alzheimer's amyloid $\beta$ A4 share similar properties and can be solubilized in buffers of pH 7.4," <u>Eur. J. Biochem.</u> , 201:61-69 (1991).
✓	534	HOCK et al., "Antibodies against $\beta$ -Amyloid Slow Cognitive Decline in Alzheimer's Disease," <u>Neuron</u> , 38:542-554 (2003).

Examiner  
SignatureDate  
Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60554673

→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 18 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.

Attorney Docket Number 15270J-004747US

<i>DK</i>	413	HOLTZMAN et al., "A $\beta$ immunization and anti-A $\beta$ antibodies: potential therapies for the prevention and treatment of Alzheimer's disease," <u>Advanced Drug Delivery Reviews</u> , 54:1603-1613 (2002).	
	122	HSIAO et al., "Correlative Memory Deficits, A $\beta$ Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> , 274: 99-102 (1996).	
	123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. Neuroimmunology</u> , 52:147-152 (1994).	
	174	Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/Graduate School of Medicine, Knoxville, Tennessee (publication date unknown).	
	124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <u>N. E. J. Medicine</u> , 333(19):1283-1284 (1995).	
	256	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- $\beta$ protein monoclonal antibody," <u>Lab. Invest.</u> , 57:446-449 (1987).	
	546	IRIZARRY et al., "A $\beta$ Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse," <u>J. Neuroscience</u> , 17(18):7053-7059 (1997).	
	125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J. Neuroimmunology</u> , 24:173-182 (1989).	
	192	IWATSUBO et al., "Visualization of A $\beta$ 42(43) and A $\beta$ 40 in Senile Plaques with End-Specific A $\beta$ Monoclonals: Evidence That an Initially Deposited Species Is A $\beta$ 42(43)," <u>Neuron</u> , 13:45-53 (1994).	
	560	JAHLING et al., "Opsonization of Alphaviruses in Hamsters," <u>J. Medical Virology</u> , 12:1-16 (1983).	
	374	JAKES et al., "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease," <u>Alzheimer Disease and Associated Disorders</u> , 9(1):47-51 (1995).	
	126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immun. Rev.</u> , 62: 185-216 (1982).	
	308	JANUS et al., "A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease," <u>Nature</u> , 408(6815):979-982 (2000).	
<i>✓</i>	257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <u>Brain Research Protocols</u> , 2:23-30 (1997).	

Examiner Signature

*Johnalyn D. Lyles*

Date Considered

1/16/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60554673

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 19 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.

Attorney Docket Number 15270J-004747US

JK	216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <i>Am. J. of Pathology</i> , 138:373-384 (1991).	
	334	JOBLING et al., "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <i>Molecular Microbiology</i> , 5(7):1755-1767 (1991).	
	449	JOHNSON-WOOD et al., "Amyloid precursor protein processing and A $\beta_{42}$ deposition in a transgenic mouse model of Alzheimer disease," <i>PNAS</i> , 94:1550-1555 (1997).	
	371	JOHNSTONE et al., Nuclear and Cytoplasmic Localization of the $\beta$ -Amyloid Peptide (1-43) in Transfected 293 Cells," <i>Biochem. Biophys. Res. Comm.</i> , 220:710-718 (1996).	
	347	JORBECK et al., "Artificial <i>Salmonella</i> Vaccines: <i>Salmonella typhimurium</i> O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," <i>Infection and Immunity</i> , 32(2):497-502 (1981).	
	127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <i>Res. Immunology</i> , 143:637-641 (1992).	
	183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <i>Biotechnol. Appl. Biochem.</i> , 23:227-230 (1996).	
	128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <i>Nature</i> , 354:476-478 (1991).	
	547	KAYED et al., "Conformational Transitions of Islet Amyloid Polypeptide (IAPP) in Amyloid Formation <i>In Vitro</i> ," <i>J. Mol. Biol.</i> , 287:781-796 (1999).	
	434	KELLY, J. W., "Alternative conformations of amyloidogenic proteins govern their behavior," <i>Current Opinion in Structural Biology</i> , 6:11-17 (1996).	
	554	KETTLEBOROUGH et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <i>Protein Engineering</i> , 4(7):773-783 (1991).	
	258	KIDA, et al., "Early amyloid- $\beta$ deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," <i>Neuroscience Letters</i> , 193:105-108 (1995).	
	488	KLEIN et al., "Targeting small A $\beta$ oligomers: the solution to an Alzheimer's disease conundrum?," <i>Trends in Neurosciences</i> , 24(4):219-224 (2001).	
✓	195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the $\beta$ A4 Peptide," <i>Annals of NY Acad. Sci.</i> , 777:344-355 (1996).	

Examiner Signature

Date Considered

1/6/06

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60554673

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 20 of 32

**Complete if Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.

Attorney Docket Number 15270J-004747US

DK	494	KOTILINEK et al., "Reversible memory loss in a mouse transgenic model of Alzheimer's disease," <u>J. Neurosci.</u> , 22(15):6331-6335 (2002).	
	465	KOUDINOV et al., "The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma," <u>Biochem. &amp; Biophys. Res. Comm.</u> , 205:1164-1171 (1994).	
	389	KOVÁCS et al., "Mutations of the Prion Protein Gene Phenotypic Spectrum," <u>J. Neurol.</u> , 249:1567-1582 (2002).	
	478	KUO et al., "High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease," <u>Biochem. Biophys. Res. Comm.</u> , 257(3):787-791 (1999).	
	477	LAMBERT et al., "Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins," <u>PNAS</u> , 95:6448-6453 (1998).	
	489	LAMBERT et al., "Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies," <u>J. Neurochem.</u> , 79:595-605 (2001).	
	129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993).	
	130	LANGER, "New Methods of Drug Delivery," <u>Science</u> , 249:1527-1532 (1990).	
	131	LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> , 57:207-213 (1993).	
	259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <u>Curr. Op. in Chemical Biology</u> , 1:260-267 (1997).	
	490	LEE et al., "Aβ immunization: Moving Aβ peptide from brain to blood," <u>PNAS</u> , 98(16):8931-8932 (2001).	
	132	LEMIERE et al., "Mucosal Administration of Aβ Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , 25(part 1), Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999).	
	260	LEMIERE, et al., "Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice," <u>Annals of the NY Acad. Sci.</u> , 920:328-331 (2000).	
	553	LEMIERE et al., "Intranasal immunotherapy for the treatment of Alzheimer's disease: <i>Escherichia coli</i> LT and LT(R192G) as mucosal adjuvants," <u>Neurobiology of Aging</u> , 23(6):991-1000 (2002).	
	551	LEVERONE et al., "Aβ1-15 is less immunogenic than Aβ1-40/42 for intranasal immunization of wild-type mice but may be effective for 'boosting,'" <u>Vaccine</u> , 21:2197-2206 (2003).	
✓	459	LEVITT, M., "Molecular dynamics of native protein," <u>J. Mol. Biol.</u> , 168:595-620 (1983).	

Examiner  
SignatureDate  
Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60554673

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 21 of 32

**Complete if Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.

Attorney Docket Number 15270J-004747US

DK	481	LEVY et al., "Immunization for Alzheimer's disease: A shot in the arm or a whiff?," <u>American Neurological Assoc.</u> , 48:553-554 (2000).
	184	LI et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol. Biol. Int.</u> , 43(3):601-611 (1997).
	133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <u>J. Immunol.</u> , 159:1383-1392 (1997).
	134	LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991).
	499	LUE et al., "Soluble $\beta$ -amyloid Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease," <u>Am. J. Pathol.</u> , 155:853-862 (1999).
	502	MAGGIO et al., "Brain Amyloid - A Physicochemical Perspective," <u>Brain Pathology</u> , 6:147-162 (1996).
	218	MAJOCCHA et al., "Development of a Monoclonal Antibody Specific for $\beta$ /A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <u>The J. of Nuclear Med.</u> , 33:2184-2189 (1992).
	261	MAK, et al., "Polyclonals to $\beta$ -amyloid (1-42) Identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Research</u> , 667:138-142 (1994).
	263	MANN, et al., "Amyloid $\beta$ protein ( $A\beta$ ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of $A\beta_{42(43)}$ ," <u>Annals of Neurology</u> , 40:149-156 (1996).
	262	MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," <u>Neuroscience Letters</u> , 196:105-108 (1995).
	408	MARSHALL, E., "Gene Therapy's Growing Pains," <u>Science</u> , 269:1050-1055 (1995).
	335	MASLIAH et al., " $\beta$ -Amyloid peptides enhance $\alpha$ -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <u>PNAS</u> , 98(21):12245-12250 (2001).
	545	MASLIAH et al., "Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F $\beta$ -Amyloid Precursor Protein and Alzheimer's Disease," <u>J. Neuroscience</u> , 16(18):5795-5811 (1996).
✓	217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>PNAS</u> , 82:4245-4249 (1985).

Examiner Signature

Date Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60554673

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 22 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.

Attorney Docket Number 15270J-004747US

DK	309	MATTSON, "Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives," <u>Physiol Rev.</u> , 77(4):1081-132 (1997).
	135	MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <u>J. Micro. Encap.</u> , 14(2):197-210 (1997).
	264	MCGEER, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <u>J. of Neuroscience Res.</u> , 31:428-442 (1992).
	479	MCLEAN et al., "Soluble pool of A $\beta$ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease," <u>Amer. Neurological Assoc.</u> , 46:860-866 (1999).
	238	MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <u>Virology</u> , 243:158-166 (1998).
	136	MEDA et al., "Activation of microglial cells by $\beta$ -amyloid protein and interferon- $\gamma$ ," <u>Nature</u> , 374:647-650 (1995).
	265	MENA, et al., "Monitoring pathological assembly of tau and $\beta$ -amyloid proteins in Alzheimer's disease," <u>Acta Neuropathol.</u> , 89:50-56 (1995).
	310	MERLUZZI, et al., "Humanized antibodies as potential drugs for therapeutic use," <u>Adv Clin Path.</u> , 4(2):77-85 (2000).
	137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991).
	367	MONSNEGO et al., "Immune hyporesponsiveness to amyloid $\beta$ -peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," <u>PNAS</u> , 98(18):10273-10278 (2001).
	311	MORGAN, et al., "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <u>Nature</u> , 408(6815):982-985 (2000).
	206	MORI et al., "Mass Spectrometry of Purified Amyloid $\beta$ Protein in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992).
	233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," <u>Neurology</u> , 39:1159-1165 (1989).
✓	359	MUNCH et al., "Potential neurotoxic inflammatory response to A $\beta$ vaccination in humans," <u>J. Neural Transm.</u> , 109:1081-1087 (2002).

Examiner  
SignatureDate  
Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60554673

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 23 of 32

**Complete if Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.
Attorney Docket Number	15270J-004747US

DK	355	MUNSON eds., <i>Principals of Pharmacology: Basic Concepts &amp; Clinical Applications</i> , pgs. 47-48, Chapman & Hall, New York, New York (1995).
	191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of $\beta$ -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <i>Am. J. Pathology</i> , 144(5):1082-1088 (1994).
	354	MUTSCHLER et al., <i>Drug Actions: Basic Principles and Therapeutic Aspects</i> pgs. 7, 11-12, Medpharm Scientific Publishers, Stuttgart, Germany (1995).
	250	NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys," <i>Exp. Anim.</i> , 43:711-718 (1995).
	268	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid $\beta$ protein (A $\beta$ ) subtypes (A $\beta$ 40 and A $\beta$ 42(43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," <i>Neuroscience Letters</i> , 201:151-154 (1995).
	281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <i>J. of Med. Primatology</i> , 27:244-252 (1998).
	439	NALBANTOGLU, J., "Beta-amyloid protein in Alzheimer's disease," <i>Can. J. Neurol. Sci.</i> , 18(3 suppl.):424-427 (1991), abstract only
	482	NASLUND et al., "Correlation between elevated levels of amyloid $\beta$ peptide in the brain and cognitive decline," <i>J. Am. Med. Assoc.</i> , 283:1571 (2000).
	138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <i>Am. J. Epidemiol.</i> , 145(11):959-969 (1997).
	139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).
	235	NEWCOMBE et al., "Solubility characteristics of isolated amyloid fibrils," <i>Biochim. Biophys. Acta</i> , 104:480-486 (1965).
	425	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," pages 492-495 from Chapter 14 of <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz et al., eds., Birkhauser Boston (1994).
	350	NICOLL et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid- $\beta$ peptide: a case report," <i>Nature Medicine</i> , 9(4):448-452 (2003).
✓	329	NIEMANN, "Transgenic farm animals get off the ground;" <i>Transgenic Research</i> , 7:73-75 (1998).

Examiner  
SignatureDate  
Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60554673

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 24 of 32

**Complete if Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.

Attorney Docket Number 15270J-004747US

DK	568	NOVOTNY et al., "Structural invariants of antigen binding: Comparison of immunoglobulin V <sub>L</sub> -V <sub>H</sub> and V <sub>L</sub> -V <sub>L</sub> domain dimmers," <u>PNAS</u> , 82:4592-4596 (1985).
	409	ORKIN et al., <i>Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy</i> , December 7, 1995
	398	PALHA et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy," <u>J. Mol. Med.</u> , 7:703-707 (2001).
	406	PAN et al., "Antibodies to $\beta$ -Amyloid Decrease the Blood-to-Brain Transfer of $\beta$ -Amyloid Peptide," <u>Exp. Biol. Med.</u> , 227(8):609-615 (2002).
	280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem. Biophys. Res. Comm.</u> , 146:307-313 (1987).
	140	PARESCHE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <u>Neuron</u> , 17:553-565 (September 1996).
	141	PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995).
	564	PCT Search Report of 12/14/04 for application PCT/US04/02856
	437	PERSSON et al., "IgG subclass-associated affinity differences of specific antibodies in humans," <u>J. Immunology</u> , 140(11):3875-3879 (1988), abstract only
	336	PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <u>PNAS</u> , 99(8):5591-5595 (2002).
	232	PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," <u>Laboratory Animal Science</u> , 46(1):8-14 (1996).
	269	PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience Res.</u> , 46:709-719 (1996).
	491	PODUSLO et al., "Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease," <u>Neurobiol. Dis.</u> , 8(4):555-567 (2001).
	142	PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8):652, column 1, abstract 86406t (1994).
✓	394	PRUSINER et al., "Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies," <u>PNAS</u> , 90:10608-10612 (1993).

Examiner Signature

Date Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60554673

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 25 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.
Attorney Docket Number	15270J-004747US

DK	460	QUEEN et al., "A humanized antibody that binds to the interleukin 2 receptor," <u>PNAS</u> , 86:10029-10033 (1989).
	143	QUON et al., "Formation of $\beta$ -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991).
	497	RAGUSI et al., "Redistribution of Imipramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies," <u>J. Neurochem.</u> , 70(5):2099-2105 (1998).
	145	RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998).
	304	RASO, V.A., Grant application # 1 R43 AGI 5746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).
	144	RASO, V.A., Grant application # 1 R43 AGI 5746-01 (redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).
	146	ROGERS et al., "Complement activation by $\beta$ -amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992).
	147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993).
	209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).
	189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993).
	194	SAIDO et al., "Spatial Resolution of the Primary $\beta$ -Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994).
	279	SAITO et al., "Vector-mediated delivery of $^{125}$ I-labeled $\beta$ -amyloid peptide Ab $^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the A $\beta$ $^{1-40}$ vector complex," <u>PNAS</u> , 92:10227-10231 (1995).
	278	SAITO, N. et al., "Immunological analysis of Alzheimer's disease using anti- $\beta$ -protein monoclonal antibodies," <u>Sapporo Med. J.</u> , 60:309-320 (1991).
	277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997).
✓	148	SCHENK et al., "Immunization with amyloid- $\beta$ attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).

Examiner  
SignatureDate  
Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60554673

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 26 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.
Attorney Docket Number	15270J-004747US

DK	178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- $\beta$ Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).	
	270	SCHENK et al., " $\beta$ -peptide immunization," <u>Arch. Neurol.</u> , 57:934-936 (2000).	
	312	SCHENK et al., "Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier," <u>DNA Cell Biol.</u> , 20(11):679-81 (2001).	
	414	SCHENK, D., "Amyloid- $\beta$ immunotherapy for Alzheimer's disease: the end of the beginning," <u>Nature Reviews</u> , 3:824-828 (2002).	
	466	SCHWARZMAN et al., "Transthyretin sequesters amyloid $\beta$ protein and prevents amyloid formation," <u>PNAS</u> , 91:8368-8372 (1994).	
	536	SELA et al., "Different roles of D-amino acids in immune phenomena," <u>FASEB J.</u> , 11(6):449-456 (1999)..	
	150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994).	
	151	SELKOE, "Physiological production of the $\beta$ -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993).	
	313	SELKOE, "The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease," <u>Trends Cell Biol.</u> , 8(11):447-53 (1998).	
	149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000).	
	155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).	
	152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (1991).	
	153	SELKOE, Dennis J., "In the Beginning..." <u>Nature</u> , 354:432-433 (1991).	
	154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991).	
	156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's $\beta$ -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992).	
✓	157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992).	

Examiner  
SignatureDate  
Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60554673

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 27 of 32

**Complete if Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.
Attorney Docket Number	15270J-004747US

DK	330	SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," <u>Arterioscler Thromb Vasc Biol.</u> , 20:1425-1429 (2000).
	400	SIGURDSSON et al., "A safer vaccine for Alzheimer's disease?," <u>Neurobiology of Aging</u> , 23:1001-1008 (2002).
	396	SIGURDSSON et al., "Anti-priori antibodies for prophylaxis following prion exposure in mice," <u>Neurosciences Letters</u> , 336:185-187 (2003).
	384	SIGURDSSON et al., "Immunization Delays the Onset of Prion Disease in Mice," <u>American Journal of Pathology</u> , 161:13-17 (2002).
	314	SIGURDSSON, et al., "In vivo reversal of amyloid-beta lesions in rat brain," <u>J Neuropathol Exp Neurol.</u> , 59(1):11-17 (2000).
	552	SIGURDSSON et al., "Immunization with a Nontoxic/Nonfibrillar Amyloid- $\beta$ Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice," <u>Am. J. Pathology</u> , 159(2):439-447 (2001).
	505	SIMMONS, L., "Secondary structure of amyloid $\beta$ peptide correlates with neurotoxic activity <i>in vitro</i> ," <u>Molecular Pharmacology</u> , 45:373-379 (1994).
	426	SINGH, K. S., "Neuroautoimmunity: Pathogenic Implications for Alzheimer's Disease," <u>Gerontology</u> , 43:79-94 (1997).
	438	SINGH, V. K., "Studies of neuroimmune markers in Alzheimer's disease," <u>Mol. Neurobiology</u> , 9(1-3):73-81 (1994), abstract only
	315	SINHA, et al., "Recent advances in the understanding of the processing of APP to beta amyloid peptide," <u>Ann N Y Acad Sci.</u> , 920:206-8 (2000).
	368	SIPE, "Amyloidosis," <u>Annu. Rev. Biochem.</u> , 61:947-975 (1992).
	337	SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotech</u> , 18(1):34-39 (2000).
	319	SMALL et al., "Alzheimer's disease and Abeta toxicity: from top to bottom," <u>Nat Rev Neurosci.</u> , 2(8):595-598 (2001).
	427	SMITH et al., "The challenges of genome sequence annotation or 'The devil is in the details,'" <u>Nature Biotechnology</u> , 15:1222-1223 (1997).
✓	158	SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3):101-105 (1997).

Examiner  
SignatureDate  
Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60554673

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 28 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.

Attorney Docket Number 15270J-004747US

<i>DK</i>	185      SOLOMON and et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <i>Adv. Mol. Cell Biology</i> , 15A:33-45 (1996).	
	186      SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown).	
	159      SOLOMON et al., "Disaggregation of Alzheimer $\beta$ -amyloid by site-directed mAb," <i>PNAS</i> , 94:4109-4112 (1997).	
	160      SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer $\beta$ -amyloid peptide," <i>PNAS</i> , 93:452-455 (1996).	
	411      SOLOMON et al., "The Amino Terminus of the $\beta$ -Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility," from <i>Progress in Alzheimer's and Parkinson's Diseases</i> , edited by Fisher et al., Plenum Press, New York, pages 205-211 (1995).	
	161      SOLOMON, A., "Pro-Rx (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown).	
	162      SOLOMON, B., "New Approach Towards Fast Induction of Anti $\beta$ -Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Ramat Aviv, Tel-Aviv, Israel (publication date unknown).	
	549      SOLOMON, B., "Immunological approaches as therapy for Alzheimer's disease," <i>Expert Opin. Biol. Ther.</i> , 2(8):907-917 (2002).	
	316      SOTO et al., "Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy," <i>Nature Medicine</i> , 4(7):822-826 (1998).	
	508      SOTO et al., "The $\alpha$ -helical to $\beta$ -strand transition in the amino-terminal fragment of the amyloid $\beta$ -peptide modulates amyloid formation," <i>J. Biol. Chem.</i> , 270(7):3063-3067 (1995).	
	179      SOUTHWICK et al., "Assessment of Amyloid $\beta$ protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <i>J. Neurochemistry</i> , 66:259-265 (1996).	
	369      SPOONER et al., "The generation and characterization of potentially therapeutic A $\beta$ antibodies in mice: differences according to strain and immunization protocol," <i>Vaccine</i> , 21:290-297 (2002).	
	271      ST. GEORGE-HYSLOP et al., "Antibody clears senile plaques," <i>Nature</i> , 40:116-117 (1999).	
<i>✓</i>	338      STEIN et al., "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," <i>The Journal of Neuroscience</i> , 22(17):7380-7388 (2002).	

Examiner Signature *Janice Kell*

Date Considered 1/6/06

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60554673

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 29 of 32

**Complete if Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.

Attorney Docket Number 15270J-004747US

JK	435	STERN et al., "Antibodies to the $\beta$ -amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood." <u>FEBS Letters</u> , 264(1):43-47 (1990).
	163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum Malaria</i> ", <u>N. Engl. J. Med.</u> , 336(2):86-91 (1997).
	496	STRBAK et al., "Passive Immunization and Hypothalamic Peptide Secretion", <u>Neuroendocrinology</u> , 58:210-217 (1993).
	164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>PNAS</u> , 94: 13287-13292 (1997).
	361	SU et al., "Intravascular infusions of soluble $\beta$ -amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," <u>Brain Research</u> , 818:105-107 (1999).
	498	SUO et al., "Soluble Alzheimers $\beta$ -amyloid constricts the cerebral vasculature in vivo" <u>Neuroscience Letters</u> , 257:77-80 (1998).
	272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid $\beta$ -peptide as modeled with N-terminal decapeptide fragments," <u>Int. J. Peptide Protein Res.</u> , 47:289-296 (1996).
	467	TABATON et al., "Soluble amyloid $\beta$ -protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid," <u>Biochem. and Biophys. Res. Comm.</u> , 200(3):1598-1603 (1994).
	392	TAL et al., "Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice," <u>Journal of Neuroscience Research</u> , 71:286-290 (2003).
	399	TAN et al., "Amyloidosis," <u>Histopathology</u> , 25:403-414 (1994).
	165	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 352:135-142 (1998).
	472	TELLER et al., "Presence of soluble amyloid $\beta$ -peptide precedes amyloid plaque formation in Down's syndrome" <u>Nature Medicine</u> , 2(1):93-95 (1996).
	339	TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," <u>PNAS</u> , 92:4299-4303 (1995).
	273	THORSETT, E.D. et al., "Therapeutic approaches to Alzheimer's disease," <u>Curr. Op. in Chem. Biology</u> , 4:377-382 (2000).
✓	500	TJERNBERG et al., "A molecular model for Alzheimer amyloid $\beta$ -peptide fibril formation," <u>J. Biol. Chem.</u> , 274(18):12619-12625 (1999).

Examiner Signature

Date Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60554673

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 30 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.

Attorney Docket Number 15270J-004747US

<i>DK</i>	276 TJERNBERG et al., "Arrest of $\beta$ -amyloid fibril formation by a pentapeptide ligand," <i>J. Biol. Chem.</i> , 271:8545-8548 (1996).	
	537 TJERNBERG, et al, "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," <i>J. Biol. Chem.</i> , 272(19):12601-12605 (1997).	
	492 TOWN et al., "Characterization of murine immunoglobulin G antibodies against human amyloid- $\beta$ ," <i>Neurosci. Lett.</i> , 307:101-104 (2001).	
	166 TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <i>Immunobiology</i> , 191(2-3):114-115 Abstract C.37, (1994).	
	375 TSUZUKI et al., "Amyloid $\beta$ protein in rat soleus in chloroquine-induced myopathy using end-specific antibodies for A $\beta$ 40 and A $\beta$ 42: immunohistochemical evidence for amyloid $\beta$ protein," <i>Neuroscience Letters</i> , 2002:77-80 (1995).	
	167 VAN GOOL et al., "Concentrations of amyloid- $\beta$ protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <i>Neuroscience Letters</i> , 172:122-124 (1994).	
	535 VAN REGENMORTEL et al, "D-peptides as immunogens and diagnostic reagents," <i>Curr. Opin. Biotechnol.</i> , 9(4):377-382 (1998).	
	317 VEHMAS et al., "beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology," <i>DNA Cell Biol.</i> , (11):713-721 (2001).	
	428 VELAZQUEZ et al., "Aspartate residue 7 in amyloid $\beta$ -protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis," <i>Nature Medicine</i> , 3(1):77-79 (1997).	
	168 VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <i>Amer. Journ. Pathology</i> , 144(1):104-116 (1994).	
	410 VERMA et al., "Gene therapy - promises, problems and prospects," <i>Nature</i> , 389:239-242 (1997).	
	569 VERSHIGORA A. E. OBSHCHAYA IMMUNOLOG/YA, pages 35, 229-231 and 152-153.	
	169 WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <i>J. Neuropath. Exp. Neurology</i> , 53(4):377-383 (1994).	
	480 WANG et al., "The levels of soluble versus insoluble brain A $\beta$ distinguish Alzheimer's disease from normal and pathologic aging," <i>Experimental Neurology</i> , 158:328-337 (1999).	
<i>✓</i>	495 WANG et al., "Soluble oligomers of $\beta$ amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus," <i>Brain Research</i> , 924:133-140 (2002).	

Examiner Signature *Janet E. Velt*

Date Considered 1/6/06

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60554673

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 31 of 32

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.
Attorney Docket Number	15270J-004747US

DK	274	WEINER et al., "Nasal administration of amyloid- $\beta$ peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <i>Annals of Neurology</i> , 48:567-579 (2000).	
	171	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <i>Annu. Rev. Immunol.</i> , 12:809-837 (1994).	
	172	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <i>Curr. Opin. Neurobiol.</i> , 7:695-700 (1997).	
	387	WELDON et al., "Neurotoxicity of A $\beta$ Peptide: Confocal Imaging of Cellular Changes Induced by – Amyloid in Rat CNS <i>In Vivo</i> ," <i>Society for Neuroscience Abstracts</i> , 22(Part 1) (1996).	
	429	WELLS, J. A., "Additivity of Mutational Effects in Proteins," <i>Biochemistry</i> , 29(37):8509-8517 (1990).	
	180	WEN, G.Y., "Alzheimer's Disease and Risk Factors," <i>J. Food Drug Analysis</i> , 6(2):465-476 (1998).	
	170	WENGENACK et al., "Targeting Alzheimer amyloid plaques <i>in vivo</i> ," <i>Nature Biotech.</i> , 18:868-872 (2000).	
	474	WINTER et al., "Humanized antibodies" <i>Immunology Today</i> , 14(6):243-246 (1996).	
	223	WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 56. (Publication date unknown.)	
	468	WISNIEWSKI et al., "Alzheimer's disease and soluble A beta," <i>Neurobiol. Aging</i> , 15(2):143-52 (1994).	
	385	WISNIEWSKI et al., "Therapeutics In Alzheimer's and Prion Diseases," <i>Biochemical Society Transactions</i> , 30(4):574-587 (2002).	
	219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <i>PNAS</i> , 82:8729-8732 (1985).	
	173	WOOD et al., "Amyloid precursor protein processing and A $\beta$ 42 deposition in a transgenic mouse model of Alzheimer disease," <i>PNAS</i> , 94: 1550-1555 (1997).	
	506	WOOD et al., "Prolines and amyloidogenicity in fragments of the Alzheimer's peptide $\beta$ A4" <i>Biochemistry</i> , 34:724-730 (1995).	
✓	275	WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier <i>in vivo</i> with a monoclonal antibody to the human insulin receptor," <i>J. Clin. Invest.</i> , 100:1804-1812 (1997).	

Examiner  
SignatureDate  
Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60554673

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 32 of 32

**Complete if Known**

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Lyles, Johnalyn D.

Attorney Docket Number 15270J-004747US

<i>DK</i>	567	WU et al., "An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity," <u>J. Exp. Med.</u> , 132:211-250 (1970).	
	507	XU et al., "Increased incidence of anti- $\beta$ -amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease," <u>Mechanisms of Ageing and Development</u> , 94:213-222 (1997).	
	292	YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid $\beta$ protein, possibly showing a disappearing stage of senile plaques," <u>Acta Neuropathol.</u> , 95:217-222 (1998).	
	430	YANG et al., "Effects of Racemization on the Aggregational Properties of the Amyloid $\beta$ -Peptide in Alzheimer's Disease," abstract # 255 from American Chemical Society 214th National Meeting (1997).	
	290	YOUNKIN, "Amyloid $\beta$ vaccination: reduced plaques and improved cognition," <u>Nature Medicine</u> , 7:18-19 (2001).	
	483	ZLOKOVIC et al., "Clearance of amyloid $\beta$ -peptide from brain: transport or metabolism?," <u>Nature Medicine</u> , 6(7):718-719 (2000).	
<i>✓</i>	580	ZLOKOVIC et al., "Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers," <u>PNAS</u> , 93(9):4229-4334 (1996) abstract only.	

Examiner  
Signature*Janell L. Loh*Date  
Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60554673

PTO/SB/08A (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

*Complete if Known*

Application Number	10/828,548
Filing Date	April 19, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	15270J-004746US

### U.S. PATENT DOCUMENTS

Examiner	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
JK	544	2003/0147882 A1		08-07-2003	Solomon	

### FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>3</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> or known				

Examiner Signature	<i>Daniel E. Klin</i>	Date Considered	1/6/06
--------------------	-----------------------	-----------------	--------

<sup>1</sup>EXAMINER: Initials of reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60280696 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTC

JUN 28 2004

**INFORMATION DISCLOSURE  
STATEMENT BY ATTORNEY**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete If Known**

Application Number	10/828,548
Filing Date	April 19, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	15270J-004746US

**U.S. PATENT DOCUMENTS**

Examiner	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
					Chain	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>3</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
JK	447	WO	03/051374	A2	06-26-2004			

Examiner Signature

Date Considered

1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60249855 v1

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
				Application Number	
				Filing Date	
				First Named Inventor	Schenk
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	15270J-004747US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DK	360	US-2003/0073655	2003-04-17	Chain	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DK	443	WO 03/074081	2003-09-12	Chain	<input type="checkbox"/>

Examiner Signature		Date Considered	1/6/06
--------------------	--	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

60197686 v1